Digital Pathology and Image Analysis

As a first adopter of digital whole slide high-resolution image capture and with nearly two decades of operations, we have resolved and pioneered multiple imaging and image analysis methodologies that are ideal for clinical trial deployment. All our services are guided by carefully optimized and rigorously documented procedures.

Key services include:

• Pathologist-directed image analysis
• Digital whole-slide brightfield and fluorescent scanning
• Multispectral imaging
• Dedicated team of imaging scientists, image analysts, and application experts, implementing customized and commercial algorithms

Each slide is digitally captured in high-resolution, whole-slide format and retained on our image servers. The larger part of the evaluation and scoring is performed by our team of trained pathologists and imaging scientists. Image scanning and analysis for clinical trials is performed in a CLIA-certified, CAP accredited laboratory.

At CellCarta, we use industry-standard scanning technology, like fluorescent and brightfield scanners from 3DHistech, Akoya, BioView, Leica Biosystems (Aperio®), Roche/Ventana, and Zeiss to enable high throughput, high resolution imaging with a fast turnaround time.

Whole slide scanning is a strategic solution for digital image archiving, image analysis, and sharing of staining results. We can provide whole-slide scanning as part of our end-to-end digital pathology services, or as a stand-alone service for your digitization programs.

Our broad portfolio of image analysis tools such as Reveal Bio’s imageDx™, Indica Labs’ HALO®, Visiopharm®, and Akoya’s inForm® help us capture the valuable data from tissues including cell phenotypes, densities and spatial biology. Our expertise in running commercially validated assays in addition to developing custom algorithms allows us to extract the information that matters for your clinical programs

Image Analysis Capabilities

• H&E, IHC, IF, single and multiplexed, brightfield and fluorescent image analysis
• Pre-clinical and clinical trial sample analysis including human (normal, diseased, and tumor tissue) and mouse models (including xenografts)
• Semi-automated algorithms developed in HALO® or Visiopharm® by our scientists and validated according to CellCarta’s quality standards
• Spatial biology measurements and nearest neighbor analysis
• Stereology based methods for systematic uniform random sampling of ROIs for pathologist scoring e.g. for microvessel density

Our team of scientists is always available for consultation to help make sense of the expansive datasets generated for your trials.

Our team at Reveal Biosciences, a company acquired by CellCarta, specializes in the generation of customized Machine Learning/Artificial Intelligence (ML/AI)-based digital assays.

Reveal’s digital pathology services, powered by the imageDx™ software platform, transforms tissue biology into actionable data across all therapeutic areas. The imageDx™platform supports a wide range of data inputs including whole slide images, genomic data, spatial data, and more. Model development is driven by machine learning and a full suite of image annotation tools that characterize tissue features, regions of interest, cell types, and staining across tissue sections.

Take your data even further with predictive AI, utilizing the power of deep learning to predict responders, stratify patient groups, and predict treatment outcomes. Flexible assay outputs and data visualization tools including heatmaps allow for fully optimized end-to-end AI models to be deployed globally in the cloud.

CellCarta is also offering AI algorithm development services using HALO® AI software. HALO® AI utilizes advanced deep learning neural network algorithms and allows training by example with advanced cell segmentation and tissue classification tools.

Download our brochure or visit Reveal Bio’s website to learn more.